

Walker Chandiook & Co LLP

Walker Chandiook & Co LLP
21st Floor, DLF Square
Jacaranda Marg, DLF Phase II
Gurugram – 122 002
India
T +91 124 4628099
F +91 124 4628001

Independent Auditor's Review Report on Unaudited Quarterly Financial Results and Year to Date Results of Jagsonpal Pharmaceuticals Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Jagsonpal Pharmaceuticals Limited

1. We have reviewed the accompanying statement of unaudited financial results ('the Statement') of Jagsonpal Pharmaceuticals Limited ('the Company') for the quarter ended 31 December 2024 and the year to date results for the period 1 April 2024 to 31 December 2024, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Chartered Accountants

Offices in Bengaluru, Chandigarh, Chennai, Gurugram, Hyderabad, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune

Walker Chandiook & Co LLP is registered with limited liability with identification number AAC-2085 and its registered office at L-41 Connaught Circus, New Delhi, 110001, India

Walker Chandiook & Co LLP

Independent Auditor's Review Report on Unaudited Quarterly Financial Results and Year to Date Results of Jagsonpal Pharmaceuticals Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Walker Chandiook & Co LLP

Chartered Accountants

Firm Registration No: 001076N/N500013

Madhu Sudan

Madhu Sudan Malpani

Partner

Membership No. 517440

UDIN: 25517440BMLKKBV1297



Place: Gurugram

Date: 22 January 2025

Jagsonpal Pharmaceuticals Limited

Corporate office: Plot No. 412-415, 3rd Floor, Nimai Tower, Phase- IV, Udyog Vihar, Sector 18, Gurugram, Haryana-122015

CIN No:- L74899DL1978PLC009181

Phone: 0124-4406710

Statement of Unaudited Financial Results for the Quarter and Nine Months Ended 31 December 2024

(Rs. in Million)

Sr. No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31 December	30 September	31 December	31 December	31 December	31 March
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
		2024	2024	2023	2024	2023	2024
	INCOME						
1	Revenue from operations	740.25	746.92	472.34	2,101.56	1,652.16	2,087.02
2	Other income	23.22	16.54	25.21	54.20	67.92	92.79
3	Total income (1+2)	763.47	763.46	497.55	2,155.76	1,720.08	2,179.81
	EXPENSES						
	a) Cost of materials consumed	52.70	52.01	58.80	148.58	183.12	221.00
	b) Purchases of stock-in-trade	211.22	215.68	139.84	627.24	419.17	539.81
	c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	1.25	(8.72)	(2.92)	(28.64)	20.84	38.96
	d) Employee benefits expense	168.15	166.75	116.42	482.29	370.47	484.93
	e) Share based payment expense	12.68	21.25	26.52	58.18	110.36	133.10
	f) Finance costs	2.55	2.29	2.26	6.99	5.97	8.14
	g) Depreciation and amortisation expense	24.13	23.41	4.12	58.26	12.60	16.63
	h) Other expenses	135.91	137.10	99.72	390.34	344.22	438.55
	Total expenses	608.59	609.77	444.76	1,743.24	1,466.75	1,881.12
5	Profit before exceptional items and tax (3-4)	154.88	153.69	52.79	412.52	253.33	298.69
6	Exceptional items (refer note 3)	231.84	-	-	198.99	-	-
7	Profit before tax (5-6)	386.72	153.69	52.79	611.51	253.33	298.69
8	Tax expense:						
	Current tax (including earlier years) (refer note 3)	80.62	26.84	13.72	123.33	65.56	75.60
	Deferred tax (credit)/charge (refer note 3)	(13.80)	12.26	(0.56)	0.40	(1.37)	(1.54)
9	Net profit for the period/year (7-8)	319.90	114.59	39.63	487.78	189.14	224.63
10	Other comprehensive income (OCI)						
	i) a) Items that will not be reclassified to profit or loss	0.84	6.60	1.52	6.80	5.22	2.67
	b) Income tax relating to items that will not be reclassified to profit or loss	(0.21)	(1.66)	(0.40)	(1.71)	(1.31)	(0.64)
	ii) a) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	b) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
11	Total comprehensive income for the period/year (9+10)	320.53	119.53	40.75	492.87	193.05	226.66
12	Earnings per share (not annualised for the quarters/periods) (refer note 5)						
	Basic (Rs.)	4.74	1.72	0.59	7.29	2.87	3.40
	Diluted (Rs.)	4.74	1.70	0.59	7.26	2.86	3.39
13	Paid-up equity share capital (face value per share Rs. 2)	132.29	132.42	131.44	132.73	131.44	132.19
14	Reserves excluding revaluation reserves (other equity)						1,741.83
	See accompanying notes to the Unaudited Financial Results						



SIGNED FOR
IDENTIFICATION
PURPOSE ONLY



Notes to the unaudited financial results:

1. The unaudited financial results have been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
2. The Company is primarily engaged in manufacturing and trading of pharmaceutical products (including active pharmaceutical ingredients) to its customers in India and overseas, which is being considered as a single reportable business segment by the chief operating decision maker.
3. During the quarter, on 15 November 2024, the Company has disposed off its Faridabad factory premises to M/s Regalia Laminates LLP. The Company has received entire consideration of ₹ 410 million. On disposal, the Company has recognised a profit of ₹ 233.59 million, which has been disclosed as an exceptional item. The corresponding current tax impact for the said transaction is ₹ 49.73 million along with the reversal of deferred tax liabilities amounting to ₹ 22.74 million.
4. During the quarter, under the Company's Employee Stock Option Plan 2022, the Company has allotted 61,351 equity shares on exercise of vested stock options by eligible employees.
5. During the quarter, on 23 October 2024, the Board of Directors of the Company approved the sub-division/split of existing equity shares having a face value of ₹ 5 each, fully paid up, into such number of equity shares having face value of ₹ 2 each fully paid-up. Subsequent to the quarter-end, post approval of shareholders through postal ballot, the Company has completed the sub-division/split of its shares and the new split value/price per share has become effective on both stock exchanges with effect from 8 January 2025. Hence, as prescribed under Ind AS, the Company has presented basic and diluted earnings per share basis the new number of shares for current as well as previous periods.
6. The above financial results for the quarter ended 31 December 2024 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 22 January 2025 and a limited review of the same has been carried out by the statutory auditors.

Place : Gurugram
Date : 22 January 2025

Manish

Manish Gupta
Managing Director



**SIGNED FOR
IDENTIFICATION
PURPOSE ONLY**

